Keywords
Bisphosphonates
Public health
Dentistry
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To verify whether there is scientific evidence proving the relationship between the use of bisphosphonates and osteonecrosis of the jaw, as well as what other risk factors may be involved. Methods: Integrative literature review, including clinical, randomized, retrospective and prospective studies carried out from 2016 to verify recent scientific evidence that investigated whether bisphosphonates increase the risk of osteonecrosis of the jaw. Only scientific articles indexed in Medline/PubMed databases were used; IBECS, Lilacs and BBO-Dentistry. Results: Eight studies were found that met the inclusion criteria, showing that the literature on osteonecrosis of the mandible related to bisphosphonates remains scarce in randomized clinical studies with control groups. However, there is already enough evidence to indicate that this risk exists, being mainly related to the use of intravenous bisphosphonates associated with the occurrence of dentoalveolar surgical trauma, not just due to the exclusive use of the drug. Final considerations: Health professionals are warned that they should indicate to patients who may need therapy with bisphosphonates that, before starting such treatment, they seek dental surgeons for dental prophylaxis and carry out the necessary dental interventions, avoiding having to carry them out while they are being treated with these drugs.
References
ALDHALAAN NA, et al. Medication-related Osteonecrosis of the Jaw: A Review. Cureus, 2020; 12(2): 6944.
ALRAHABI MK e GHABBANI HM. Clinical impact of bisphosphonates in root canal therapy. Saudi Medical Jornal, 2018; 39(3): 232-238.
BETH-TASDOGAN NH, et al. Interventions for managing medication-related osteonecrosis of the jaw. The Cochrane Database of Systematic Reviews, 2017; 10(10): CD012432.
CALVANI F, et al. Efficacy of bovine lactoferrin in the post-surgical treatment of patients suffering from bisphosphonate-related osteonecrosis of the jaws: an open-label study. Biometals, 2018; 31(3): 445-455.
CHAMBRONE L. Current status of the influence of osteoporosis on periodontology and implant dentistry. Current Opinion in Endocrinology, Diabetes, and Obesity, 2016; 23(6): 435-439.
CHRCANOVIC BR, et al. Bisphosphonates and dental implants: A meta-analysis. Quintessence International, 2016; 47(4): 329-342.
DE-FREITAS NR, et al. Bisphosphonate treatment and dental implants: A systematic review. Medicina Oral, Patologia Oral y Cirugia Bucal, 2016; 21(5): 644-651.
DEMIRCAN S e IŞLER SC. Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: A case control study. Nigerian Journal of Clinical Practice, 2020; 23(2): 154-158.
HASEGAWA T, et al. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporosis International, 2017; 28(8): 2465-2473.
KHAN AA, et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. Journal of Clinical Densitometry, 2017; 20(1): 8-24.
LEIZAOLA-CARDESA IO, et al. Bisphosphonates, vitaminD, par-athyroid hormone, and osteonecrosis of the jaw. Could there be a missing link? Medicina Oral, Patologia Oral y Cirugia Bucal, 2016; 21(2): 236-240.
MANFREDI M, et al. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zole-dronic acid for bone metastases from solid tumors. Medicina Oral, Patologia Oral y Cirugia Bucal, 2017; 22(3): 342-348.
MANZANO-MORENO FJ, et al. Impact of bisphosphonates on the proliferation and gene expression of human fibroblasts. International Journal of Medical Sciences, 2019; 16(12): 1534-1540.
MENDES V, et al. Impact of bisphosphonate therapy on dental implant outcomes: An overview of systematic review evidence. International Journal of Oral and Maxillofacial Surgery, 2019; 48(3): 373-381.
MÜCKE T, et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. Journal of Cranio-Maxillo-Facial Surgery, 2016; 44(10): 1689-1693.
NICOLATOU-GALITIS O, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019; 127(2): 117-135.
PATNTIRAPONG S, et al. Inhibition of macrophage viability by bound and free bisphosphonates. Acta Histochemical, 2019; 121(4): 400-406.
PEXE M, et al. Estudo retrospectivo da osteonecrose dos maxilares associada ao uso de bisfosfonatos sem exposição óssea clínica. Revista Salusvita, 2018; 37(4): 867-878.
QUINTANA-GONZÁLEZ M, et al. Estado cualitativo y cuantitativo óseo generalizado en la osteonecrosis de maxilares. Efecto de los bifosfonatos. Revista de Osteoporosis y Metabolismo Mineral, 2019; 11(2): 55-63.
SHUDO A, et al. Long-term oral bisphosphonates delay healing after tooth extraction: a single institutional prospective study. Osteoporosis International, 2018; 29(10): 2315-2321.
TAGUCHI A, et al. Adequate Treatment of Osteoporosis (A-TOP) research group. Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. Journal of Bone and Mineral Metabolism, 2019; 37(5): 886-892.